Four and a half LIM domain protein-2 (FHL2) is a component of the focal adhesion structures and has been suggested to have an important role in cancer progression. This study analyses the role of FHL2 in peritumoural fibroblasts of sporadic and hereditary non-polyposis colorectal cancer (HNPCC). Tissue specimens of 48 sporadic and 49 hereditary colon cancers, respectively, were stained immunohistochemically for FHL2, transforming growth factor (TGF)-b1 ligand and a-SMA. Myofibroblasts at the tumour invasion front co-expressed a-SMA and FHL2. Sporadic colon cancer but not HNPCC cases showed a correlation between TGF-b1 expression of the invading tumour cells and FHL2 staining of peritumoural myofibroblasts. Overexpression of FHL2 in peritumoural myofibroblasts correlated to lymphatic metastasis in sporadic colon cancer but not in HNPCC. In cultured mouse fibroblasts, TGF-b1 treatment induced myofibroblast differentiation, stimulated FHL2 protein expression and elevated number of migratory cells in transwell motility assays, suggesting that FHL2 is regulated downstream of TGF-b. Physical contact of colon cancer cells and myofibroblasts via FHL2-positive focal adhesions was detected in human colon carcinoma tissue and in co-culture assays using sporadic as well as HNPCC-derived tumour cell lines. Our data provide strong evidence for an important role of FHL2 in the progression of colon cancers. Tumour-secreted TGF-b1 stimulates FHL2 protein expression in peritumoural fibroblasts, probably facilitating the invasion of tumour glands into the surrounding tissue by enhanced myofibroblast migration and tight connection of fibroblasts to tumour cells via focal adhesions. These findings are absent in HNPCC-associated colon cancers in vivo and may contribute to a less invasive and more protruding tumour margin of microsatellite instable carcinomas.
Four and a half LIM domain protein-2 (FHL2) was first identified as a protein differentially expressed in human myoblasts and rhabdomyosarcoma cells, and thus named DRAL (downregulated in rhabdomyosarcoma LIM protein 1 ). FHL2 is a LIM-only protein with four complete and one N-terminal half LIM domains that mediate protein-protein interactions.
2 FHL2 associates with integrin receptors to form focal adhesion contacts and binds signal transducers such as b-catenin. [3] [4] [5] Triggered by lipid-induced signalling, such as sphingosine-1-phosphate, FHL2 translocates into the nucleus where it binds several transcription factors including serum response factor, AP1 and androgen receptor and functions as a coactivator or a corepressor to modulate gene expression. [6] [7] [8] We showed previously that FHL2 is strongly upregulated in mesenchymal cells of wounded skin, and demonstrated a function of FHL2 in myofibroblasts regulating their migration and contraction during cutaneous wound healing. 9 Furthermore, FHL2 is critically involved in matrix assembly allowing migration of cells into the wound area. 10 Analogous to wound healing invasive carcinomas generate a specialised tumour stroma and deposit a matrix facilitating invasion into the surrounding tissue. 11 This tissue remodelling is induced by pro-metastatic factors, such as transforming growth factor (TGF)-b1, which is secreted by the tumour cells inducing the conversion of mesenchymal cells into myofibroblasts. [12] [13] [14] [15] A number of studies from our laboratory and other groups provide evidence that FHL2 is involved in cancer progression. [16] [17] [18] [19] [20] [21] Elevated expression of FHL2 and interaction with focal adhesion kinase (FAK) was found in human ovarian cancers, indicating a role of FHL2 and FAK complex during ovarian tumour progression. 17 We showed recently that activation of nuclear FHL2 signalling is linked to an aggressive biology and recurrence of prostate cancer. 18 Wang et al 21 showed that suppression of FHL2 in gastric and colon cancer cell lines induces cell differentiation and inhibits tumorigenesis. Analysing various colon cancer cell lines, Zhang et al 19, 20 showed that FHL2 expression and epithelialmesenchymal transition (EMT) can be induced by TGF-b1.
This study aimed to determine the role of FHL2 in progression of colorectal carcinoma focussing on stromal fibroblasts. As TGF-b1 is known as a signalling molecule promoting invasion of colorectal cancer, we asked specifically whether TGF-b1 signalling is able to modulate FHL2 expression and determined, whether FHL2 expression patterns provide prognostic information concerning aggressive biology and metastasis. We specifically compared FHL2 expression in sporadic and microsatellite-instable hereditary (hereditary non-polyposis colorectal cancer (HNPCC)) colon cancers, which are known to invade in a less aggressive and more protruding-type manner 22 and reveal less EMT.
MATERIALS AND METHODS Patient Collective
Paraffin-embedded tissue specimens of 97 patients were examined comprising 48 cases of sporadic colon cancer and 49 cases of hereditary HNPCC patients with proven germline mutation in mismatch repair genes. Clinical data are summarised in Table 1 
Immunohistochemistry and Immunofluorescence
Staining procedure for TGF-b1 ligand, FHL2 and a-SMA Haematoxylin-eosin staining was performed for routine pathological evaluation followed by staining and subsequent evaluation of TGF-b1 ligand, FHL2 and a-SMA. Immunohistochemical a-SMA staining was carried out as described before. 23 The staining procedure for TGF-b1 ligand and FHL2 was carried out as described briefly: tissue sections were incubated overnight at 601C, deparaffinised for 2 Â 10 min in xylene, followed by 5 min in 100% ethanol. Then slides were put for 5 min in 96% and subsequently in 70% ethanol and for another 5 min in distilled water. For better antigen retrieval, samples were boiled in a microwave oven in citrate buffer (pH 6.0). Then samples were cooled down for 20 min, washed in PBS for 5 min and incubated for 10 min in 10% normal pig serum. The samples were incubated over night at 41C with rabbit anti-human FHL2 antibody (Schüle Laboratory) used at a dilution of 1:250 or with rabbit anti-human TGF-b1 ligand antibody (clone sc-146, Santa Cruz, Santa Cruz, CA, USA) at a dilution of 1:50 for 1 h at room temperature. The samples were washed twice for 5 min in PBS and then incubated at room temperature for 30 min with the biotinylated secondary antibody. Subsequently, a washing step in PBS for 5 min and a peroxidase block with H 2 O 2 for 10 min was carried out. After washing in PBS for 5 min, streptavidine horseradish peroxidase was applied for 30 min followed by washing in PBS and subsequent visualisation with diaminobenzidine tetrahydrochloride (Sigma, Hamburg, Germany). Abbreviation: HNPCC, hereditary non-polyposis colorectal cancer.
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After a final washing step, slides were counterstained with Mayer's haematoxylin, dehydrated and mounted. Immunofluorescence stainings using the antibodies mentioned above were performed as described before. 24 Evaluation of immunohistochemical staining intensities of TGF-b1 ligand and FHL2 Evaluation of immunohistochemical staining intensities was restricted to the carcinoma invasion front. TGF-b1 ligand expression of invasive tumour epithelia or FHL2 expression of peritumoural fibroblasts at the invasion front were analysed using a four-tier scoring system: staining intensity was set to score value '0' if no staining was present. Score '1 þ ' was used if weak staining of cells was observed, score '2 þ ' if moderate and score '3 þ ' if strong staining of cells was detected. Overexpression of the respective marker was diagnosed if staining reaction was classified as '2 þ ' or '3 þ '. In cases with heterogeneous staining reactions, eg, because of varying tumour differentiation, the immunoreactive score was determined analysing the predominant area of tumour differentiation. Immunohistochemical scoring was carried out by a trained pathologist (NF) who was blinded for the results of follow-up data and data used for subsequent statistical analyses.
Immunofluorescence Microscopy
Images were taken by using a Leica TCS SP2 AOBS spectral confocal microscope (Leica, Solms, Germany) or a Leica DMLB2 fluorescence microscope (Leica, Solms, Germany) equipped with the image analysis software 'Diskus' (Diskus, Königswinter, Germany).
Western Blot
Soluble protein lysates were extracted in 150 mM NaCl, 10 mM Tris (pH 7.2), 0.1% SDS, 1% Triton X-100, 1% deoxycholate and 5 mM EDTA and centrifuged at 13 000 g for 20 min at 41C. Protein lysates (15 mg) were denatured at 901C for 10 min, run on 12% SDS-PAGE gels and electroblotted to a PVDF membrane (Roti-PVDF, Roth GmbH, Karlsruhe, Germany) using standard protocols. After blocking in 5% non-fat dry milk/PBST for 2 h, the membranes were incubated for 1 h with a mouse monoclonal anti-FHL2 antibody 25 (dilution 1:2000), a mouse monoclonal anti-a-SMA antibody (dilution 1:600; DAKO, Glostrup, Denmark), washed, incubated with horseradish peroxidase-conjugated secondary antibody (dilution 1:1000; Dako, Hamburg, Germany) and developed using ECL chemiluminescence (Amersham Biosciences, Little Chalfont, UK). As a control, blots were probed with an anti-a-tubulin antibody (dilution 1:5000, Sigma, Hamburg, Germany).
Tissue Culture
Murine embryonal fibroblasts were derived from 14.5-daysold embryos of C57BL/6 wild-type or FHL2-deficient mice as described previously. 9 Mouse fibroblasts were plated onto 15 cm dishes and grown to 75% confluency in DMEM supplemented with 10% FCS. Then the cells were grown in low serum (DMEM supplemented with 0.5% FCS) for 48 h and treated with 2 ng/ml recombinant human TGF-b1 (Tebu, Offenbach, Germany) in low serum conditions for different time points (0, 24, 72 and 96 h). The medium was changed every 24 h. For each time point, starved cells incubated with low serum were used as control. All experiments were repeated at least three times.
Co-culture Assay of Fibroblasts and Tumour Cell Lines
Fibroblasts were seeded using DMEM supplemented with 10% FBS followed by a 48 h interval of low serum conditions. Subsequently, TGF-b1 ligand (2 ng/ml) was added to fibroblast culture for 48 h. In parallel, colon cell lines were cultured in low serum conditions (0.5% FBS) for 48 h. TGF-b1 ligand (2 ng/ml) was added to co-culture (25 000 fibroblasts/ml and 25 000 tumour cells/ml) for 24 h followed by fixation of the cells and immunofluorescence staining (described below). For co-culture assays, microsatellite-stable (HT-29) and -instable colon carcinoma cell lines (HCT-116) were used.
Transwell Motility Assay
Transwell motility assays were performed as described before. 26 In brief, fibroblasts were seeded using DMEM supplemented with 10% FBS followed by a 48 h interval of low serum conditions. Subsequently, TGF-b1 ligand (2 ng/ml) was added to fibroblast culture for 72 h. In all, 100 000 cells in medium containing 0.5% FBS were added into the upper chambers of transwells of 6.5 mm diameter and 8.0 mm pore size (Corning Costar Corporation, Bodenheim, Germany). FBS concentration in the lower chamber was 2%. TGF-b1 ligand (2 ng/ml) was added to the lower chamber. The dishes were incubated in a 371C incubator (5% CO 2 ) for 6 h before removing the medium from the top wells. Membrane fixation was performed with 4% paraformaldehyde for 15 min. After removal of the non-migrating cells from the upper chamber with a cotton swab, the membranes were stained with Harris' haematoxylin for 15-20 min and washed. Membranes were removed from the plastic holders and mounted on glass slides with Aquatex (Merck, Darmstadt, Germany). The migrated cells were counted in at least 10 fields of view ( Â 200 magnification). All assays were performed in triplicate.
In a second co-culture transwell motility assay, HCT116 tumour cells were labelled with red QDot dye (Invitrogen, Darmstadt, Germany) and incubated with FHL2 wild-type or knockout (KO) fibroblasts labelled with green QDot dye. To quantify the amount of migrated tumour cells, the area covered by red fluorescence signals was calculated by imaging software analysing 10 fields of view at Â 200 magnification.
Statistical Analyses
Fisher's exact test or Mann-Whitney U-test was applied using Prism software (Graph Pad Prism, La Jolla, CA, USA).
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In sporadic colon cancer collective, four cases were not included in statistical analyses, as nodal status was not known (pNx). In the analysis of TGF-b1 and FHL2 expression in sporadic colon cancer three additional cases were excluded because of insufficient immunoreactivity for TGF-b1.
In HNPCC collective, five cases were not included in statistical analyses, as nodal status was not known (pNx). In the analysis of TGF-b1 and FHL2 expression in HNPCC, five additional cases were excluded because of insufficient immunoreactivity for TGF-b1. Pronounced accumulation of myofibroblasts at the tumour invasion front was observed in most cases of sporadic colon cancer cases vanishing with growing distance from tumour glands (Figures 2a and c) . In contrast, HNPCCassociated carcinomas showed dense lymphocytic infiltrates separating tumour epithelia from the surrounding normal tissue (Figures 2b and d) .
RESULTS

FHL2 Is Differentially Expressed in
Expression of FHL2 correlated with lymphatic metastasis (Table 2a) in sporadic colon cancer (P ¼ 0.02502) and, inversely, in HNPCC (P ¼ 0.03204).
TGF-b1 Ligand Expression in Non-neoplastic and Neoplastic Colon Specimens
In normal colon mucosa, TGF-b1 ligand was expressed in a faint, dot-like staining pattern located below the mucus plug of the enterocytes (Supplementary Figure 3A) . In colon adenomas, frequently a strong dot-like staining of tumour cells below the mucus plug (Supplementary Figure 3A) was seen. In colon carcinoma, the expression of TGF-b1 ligand in tumour cells was variable (Supplementary Figures 3B, C) . (Table 2b) was detected in sporadic carcinoma cases (P ¼ 0.00355) but not in HNPCC (P ¼ 0.33730). In contrast, colon carcinomas, which lacked TGF-b1 ligand expression showed absence Figure 4) .
TGF-b1-Treated Fibroblasts Show Enhanced FHL2 and Stable a-SMA Expression
We examined FHL2 protein expression after 0, 24, 72 and 96 h of TGF-b1 treatment (Figure 4) . In wild-type fibroblasts, FHL2 protein expression was induced after 3 days of stimulation and persisted over basal levels for the entire period until 96 h. FHL2 expression was entirely absent in murine fibroblasts isolated from FHL2 KO mice 9 before and after TGF-b1 treatment. a-SMA expression was not altered after TGF-b1 treatment of both wild-type and KO fibroblasts (Figure 4 ).
Subcellular Localisation of FHL2 and a-SMA in Cultured
Fibroblasts is Altered After TGF-b1 Treatment In cultured fibroblasts, subcellular localisation of FHL2 was significantly changed by TGF-b1 treatment and translocated to focal adhesion contacts (Figures 5a and b) . In wild-type fibroblasts, a-SMA was homogenously expressed and not well organised (Figure 5a) . After 48 h of treatment with TGF-b1, a-SMA exhibited a typical localisation in stress fibres ranging through the entire cytoplasm and connected to focal adhesion contacts (Figures 5a and b) . Fibroblasts derived from FHL2 KO mice, as expected, showed no FHL2 staining before and after TGF-b1 treatment and lacked recruitment of a-SMA into stress fibres. These data strongly suggest that FHL2 is involved in TGF-b1 signal transduction with respect to regulating a-SMA, stress fibre organisation and a myofibroblast-like morphology.
From these data, we conclude that mouse primary fibroblasts increase FHL2 expression in response to TGF-b1 treatment and express constant levels of a-SMA, with a marked reorganisation of the cytoskeleton and an increased incorporation of a-SMA into stress fibres, resulting in a myofibroblast-like cell phenotype. Importantly, FHL2 subcellular localisation to focal adhesions is also regulated by TGF-b1.
TGF-b1 treatment and FHL2 expression elevated number of fibroblasts with the capacity to migrate A transwell motility assay was applied to study the influence of TGF-b1 treatment on the number of fibroblasts with the Figure 6a) . A larger number of migrating cells was seen in TGF-b1-treated wild-type fibroblasts compared with untreated wild-type fibroblasts (Po0.001, Figure 6a ). TGF-b1 treated FHL2 KO fibroblasts showed a significantly lower number of migrating cells compared with TGF-b1 treated wild-type cells (Po0.001, Figure 6a ). TGF-b1-treated KO fibroblasts showed a significantly higher number of migrating cells (Po0.001, Figure 6a ) than untreated KO fibroblasts (Figure 6a) . In a co-culture transwell motility assay, HCT116 tumour cells were labelled with red dye and incubated with FHL2 wild-type or KO fibroblasts labelled with green dye. The co-incubation assay with wild-type fibroblasts showed more tumour cell signals than the assay co-incubated with KO fibroblasts (Supplementary Figure 5) . Though, we often observed a co-labelling of cells precluding a proper visual separation of individual cells. This co-labelling of cells might be explained by the ability of fibroblasts to perform phagocytosis 27 or by overlap of cytoplasmic tails of two individual cells with different dye label.
Contact of Tumour Cells and Myofibroblasts In Vivo and In Vitro
To analyse the contact of FHL2-positive myofibroblasts and colon cancer cells, paraffin-embedded human colon cancer tissue was stained for FHL2 and a-SMA. A direct contact of myofibroblasts to tumour cells could be observed in sporadic colon cancer in vivo (Figures 6b-d) .
Furthermore, an in vitro co-culture assay was established using sporadic (HT29) and HNPCC-derived (HCT116) colon cancer cell lines. Immunofluorescence stainings revealed that murine myofibroblasts were directly connected to tumour cells via FHL2-positive focal adhesion contacts in sporadic colon cancer cell lines as well as in HNPCC-derived cell lines (Figures 6e and f) .
DISCUSSION
This study analysed the role of the LIM-only protein FHL2 in tumour progression of sporadic colon cancer and HNPCC focussing on peritumoural myofibroblasts.
The role of FHL2 in tumorigenesis has been analysed in various cancer type, including carcinomas of the ovary, 17 the breast, 16 the prostate 18 and the gastrointestinal tract. 19, 20 These studies mainly focussed on the role of FHL2 expression in malignant tumour cells proper. However, in addition to its expression in tumour cells, FHL2 might serve as a marker for characterisation of myofibroblast-like stromal fibroblasts in the tumour micromilieu. We previously determined an important role of FHL2 in myofibroblasts during wound healing. 9 It has been shown that wounded tissue is comparable in several aspects to the tumour stroma as both are characterised by activated, a-SMA-expressing myofibroblasts and deposition of provisional matrix and basal membrane molecules. 11 As previous studies 19, 28 described an induction of FHL2 expression by TGF-b1, this study considered both markers in the systematic analysis of colorectal tumour tissue and tumour stroma in vitro and in vivo.
Previous studies reported on the relevance of TGF-b1-mediated tumour tissue remodelling for metastasis 29 and also its specific role in progression of colon cancer. 30 Therefore, we determined the expression patterns of FHL2, TGF-b1 and a-SMA, and their respective localisation in the micromilieu of sporadic and HNPCC-associated microsatellite-instable colon cancer in vivo. Normal colon mucosa showed no significant FHL2 expression of stromal fibroblasts, a finding which was also described by a previous study. 21 In contrast, carcinoma tissue displayed elevated expression of FHL2 in stromal cells, which were identified as a-SMA-positive myofibroblasts. Even in colon adenoma without signs of invasive growth myofibroblasts in direct contact to neoplastic epithelium revealed FHL2 expression indicating early preneoplastic stromal transformation. In 3D-reconstructions of peritumoural myofibroblasts by confocal microscopy, FHL2 protein was found in the cytoplasm and in the nucleus of these stromal cells (Supplementary Movies 2A-C). This observation confirms previous studies, which found that FHL2 serves as a signalling molecule and translocates into the nucleus acting as a transcriptional coactivator and corepressor. 6, 8, 25, 31 Importantly, according to our data stromal FHL2 overexpression and the presence of myofibroblast-like stromal cells provided a significant parameter for lymphatic metastasis in sporadic colon cancer. In contrast, strong stromal FHL2 expression of HNPCC-associated tumours did not show prognostic relevance with regard to lymphatic spread, indicating that myofibroblastic remodelling of the tumour stroma may differ in these microsatellite-instable carcinomas. It is well known that HNPCC-associated colon cancers show a less invasive and more protruding, pushing-like tumour periphery, 22 a lesser degree of EMT and reveal a better stageadjusted overall survival.
In this study, a positive correlation between TGF-b1 expression of the tumour cells and FHL2 expression of the stromal cells was detected in sporadic colon cancer corresponding to observations of other studies. 28 In contrast, FHL2 expression in colon cancer L Gullotti et al significant correlation of TGF-b1 expression and stromal FHL2 staining was not found in HNPCC-associated cancers, indicating that TGF-1 signalling from microsatellite-instable colon cancer cells may be defective. A histological difference between sporadic and HNPCC-associated cancers is the presence of dense lymphocytic infiltrates in the tumour micromilieu. 22 Schwitalle et al 32, 33 recently showed that frameshift-induced neopeptides in HNPCC may induce this characteristic immune response. We therefore speculate that TGF-b1-mediated interactions with myofibroblast-like stromal fibroblasts are altered in the presence of the immune response in HNPCC.
In cell culture assays of this study, TGF-b1 induced FHL2 protein expression in fibroblasts. After induction, a Figure 6 TGF-b1 treatment and FHL2 expression elevate number of fibroblasts with the capacity to migrate (a) (***Po0.001, **P ¼ 0.001 to o0.05). In sporadic human colon carcinoma contact of a FHL2 þ /a-SMA þ myofibroblast (yellow arrow) and a FHL2 þ /a-SMAÀ tumour cell (red arrow) can be observed (b, overlay; c, FHL2 staining; d, a-SMA staining with insert showing the myofibroblast in detail). In vitro, co-culture assays show direct contact of fibroblasts (marked with yellow arrows) and tumour cells via focal adhesions in sporadic colon carcinoma cell line HT29 (marked with red arrows; e) but also in HNPCC cell line HCT-116 (marked with red arrows; f; confocal pictures: images b-d: scale bar ¼ 36 mm, images e, f: scale bar ¼ 50 mm).
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L Gullotti et al myofibroblast-like differentiation was observed as described previously. 7, 34 Myofibroblasts coexpressed a-SMA and FHL2 with a characteristic expression pattern of FHL2 at focal adhesion contacts as also observed in wounded tissue. 9 It is therefore likely that TGF-b1-induced, FHL2 overexpressing myofibroblasts form a highly mobile tumour stroma favouring migration, invasive growth and dissemination of colon cancer cells. The leading role of myofibroblasts in invasive growth of carcinomas has recently been described by Gaggioli et al, 35 who found that squamous cell carcinoma cells move collectively within tracks in the extracellular matrix behind the leading fibroblast remodelling the extracellular matrix. As TGF-b1 is chemotactic for fibroblasts, 36 the in vitro setting described above may well be transferred to in vivo cancer development.
Our in vitro data showed an elevated number of FHL2 wild-type fibroblasts with the capacity to migrate compared with FHL2 KO fibroblasts. This effect was also described previously concerning the role of fibroblasts in wound healing. 9 These data point to an important role of FHL2 in migration of fibroblasts in general. Furthermore, we showed that treatment of fibroblasts with TGF-b1 went along with a higher number of cells with the capacity to migrate, a finding which has also been reported in the literature before. 15 In co-culture assays of this study, a connection of tumour cells to fibroblasts via focal adhesions was observed and detected both in sporadic and HNPCC-derived cell lines. As the dense peritumoural lymphocytic infiltrate typically found in HNPCC-associated cancers is not present in this co-culture assay, we speculate that the tight physical interaction between tumour cells and fibroblasts may be disturbed in vivo.
Taken together, the results of this study point to an important role of FHL2 in tumour-induced tissue remodelling, invasion and lymphatic metastasis of sporadic colorectal cancer, probably mediated by TGF-b1-induced, FHL2-overexpressing myofibroblasts at the tumour invasion front. On the basis of our in vitro and in vivo findings, we postulate a model that in sporadic colon cancer tumour-secreted TGF-b1 induces FHL2 expression in peritumoural myofibroblasts promoting the migration of 'leading' tumour cells into the surrounding stroma (Figure 7a ). This phenomenon has been FHL2 expression in colon cancer L Gullotti et al described previously for squamous cell carcinomas. 35 These changes in the tumour micromilieu are not present in HNPCC-associated carcinomas, and we speculate that the extensive lymphocytic immune response may alter the TGF-b1-mediated effects on stromal fibroblasts resulting in a less invasive growth pattern and less frequent lymphatic metastasis ( Figure 7b ). As FHL2 overexpression of myofibroblasts in sporadic colon cancer was significantly linked to lymphatic metastasis, we here propose FHL2 as a new prognostic marker indicating risk of lymphatic spread in colon cancers.
